Semax + Selank Stack
A research overview of the combined use of Semax and Selank, two mechanistically complementary synthetic peptides developed at the Russian Academy of Sciences. Semax has a stimulatory nootropic profile; Selank has an anxiolytic profile. Both are Animal Studies evidence compounds with clinical approval in Russia only.
Science simplified
The Focus Stack combines Semax and Selank, two Russian-developed neuropeptides that work through complementary brain pathways. Semax increases BDNF, the brain's main growth and repair factor, supporting focus and cognitive performance. Selank modulates anxiety and stress without sedation. Together they target both the cognitive performance and the anxiety-reduction sides of mental clarity. Both are approved in Russia but not FDA-approved. Western clinical data is limited.
Best researched for
Cognitive focus · anxiety reduction · mental clarity
Evidence stage
Russian approval · limited Western replication
Approval status
Approved in Russia · not FDA-approved
Animal Studies
Each Compound
None
Combination Trial Data
2
Compounds
Russia Only
Regulatory Approval
PSI Verdict
Supported by evidence
Semax and Selank address cognitive function and stress response through distinct mechanisms. Semax primarily upregulates BDNF and promotes cognitive enhancement. Selank modulates GABA and serotonin systems for anxiolytic effects. The combination targets both cognitive performance and anxiety reduction simultaneously, with each compound's mechanism validated independently in Russian clinical research.
Not yet established
Combination evidence does not exist. The cognitive enhancement plus anxiety reduction rationale is mechanistically plausible but has not been tested in combination trials. Independent Western replication of either compound's effects remains absent, which compounds the uncertainty of the stack.
Confidence level
Semax and Selank are individually the most evidence-supported cognitive peptides from the Russian research ecosystem. That ecosystem's limitations apply equally to the stack. The mechanistic pairing is rational. The evidence base for the combination, and for either compound outside Russian research, remains unvalidated by independent standards.
Stack Rationale
Mechanistic basis: Semax and Selank are examined together because their neurochemical profiles are complementary rather than redundant. Semax acts primarily through BDNF upregulation and melanocortin receptor activation, producing a stimulatory cognitive effect. Selank acts primarily through enkephalinase inhibition and GABAergic modulation, producing an anxiolytic and calming effect.
Theoretical rationale: Anxiety-related cognitive interference, where heightened arousal or stress degrades attentional performance, is a well-documented phenomenon. The hypothesis underlying this combination is that Selank's anxiolytic effects may reduce cognitive interference while Semax's nootropic effects support attentional activation. This rationale is mechanistic and has not been tested in combination trials.
Important limitation: No clinical or preclinical studies have evaluated Semax and Selank in combination. The stack rationale is derived entirely from the individual compound profiles. Interaction effects, safety of combined use, and additive or synergistic outcomes are unknown.
In everyday terms: Semax and Selank work on different but complementary brain systems. Semax increases BDNF, think of it as fertilizer for your brain cells, supporting focus and cognitive performance. Selank calms the anxiety pathways without sedation. The combination targets both sides of mental clarity, sharpening focus while reducing the cognitive interference that anxiety creates.
Compound Profiles
A synthetic ACTH(4-10) analogue that upregulates BDNF and activates melanocortin receptors without stimulating adrenal cortisol production. Studied for cognitive enhancement and neuroprotection in Russian clinical settings. Approved in Russia for cognitive impairment and stroke recovery. Primary effect profile is activating, improved attention, processing speed, and learning consolidation.
A synthetic tuftsin analogue that inhibits enkephalin degradation and modulates GABAergic tone, producing anxiolytic effects without sedation. Studied for generalized anxiety and stress-related cognitive impairment in Russian clinical settings. Approved in Russia for anxiety disorders. Primary effect profile is calming, reduced anxiety, improved stress tolerance, mild cognitive support.
Mechanistic Comparison
| Dimension | Semax | Selank |
|---|---|---|
| Primary target | Melanocortin receptors (MC3R, MC4R) | Enkephalinase inhibition |
| BDNF effect | Strong upregulation | Moderate upregulation |
| GABAergic effect | Minimal | Significant modulation |
| Effect profile | Activating / stimulatory | Calming / anxiolytic |
| Cortisol effect | None (MC2R not activated) | None documented |
| Evidence level | Animal Studies | Animal Studies |
Evidence Assessment
What people commonly research this for
- , Cognitive focus and mental performance research
- , Anxiety reduction without sedation or dependence
- , Neuroprotection and brain health protocols
Both compounds approved in Russia. No Western clinical trials. Not FDA-approved. Evidence concentrated in Russian-language literature.
Individual Compound Evidence
Both compounds are rated Animal Studies (Preliminary). Each has Russian clinical approval and a body of preclinical and limited human data. Semax has human data in cerebrovascular conditions and cognitive impairment. Selank has human data in generalized anxiety disorder. Neither has been evaluated in Western randomized controlled trials.
Combination Evidence
No studies have examined Semax and Selank in combination. The stack rationale is mechanistic. Whether the compounds interact pharmacokinetically, produce additive or synergistic cognitive effects, or carry additional safety considerations when combined is not established in published research.
Safety Considerations
Individual Safety Profiles
Russian clinical data for each compound individually reports a favorable safety profile. Semax does not elevate cortisol. Selank does not produce benzodiazepine-type dependence or sedation. Both are delivered intranasally. Mild nasal irritation is the most commonly reported adverse effect for each.
Combination Safety. Unknown
No safety data exists for combined use. Drug interaction potential, combined CNS effects, and cumulative dosing considerations have not been studied. The apparent mechanistic complementarity does not guarantee safety in combination. Caution is warranted.
Regulatory Status
Both compounds are approved in Russia. Neither is FDA-approved. Neither has been submitted for review by the EMA or other major Western regulatory bodies. Both are available internationally as research peptides.
Explore Further
Researchers interested in the individual mechanisms behind this stack can review the full compound profiles for Semax and Selank.
A direct mechanistic comparison of the two compounds is available in the Selank vs Semax comparison.
For a broader overview of peptides studied for attentional and cognitive performance, see the peptides for focus roundup.
This stack is reviewed in the context of the broader brain fog and cognitive dysfunction literature on this site.
The individual compounds in this protocol are covered in the focus condition overview.
Medical Disclaimer
This page is for informational and educational purposes only and does not constitute medical advice. Semax and Selank are research compounds not approved for human therapeutic use in most jurisdictions. Always consult a qualified healthcare professional. PSI aggregates publicly available research and does not conduct original clinical trials.